Sanofi And Regeneron's Dupixent Meets Endpoints, Accepted For Priority Review By FDA
Reuters
Nov 07
Nov 7 (Reuters) - Sanofi SA :: *ACAAI: SANOFI AND REGENERON’S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCING SIGNS AND SYMPTOMS OF ALLERGIC FUNGAL RHINOSINUSITIS; SBLA ACCEPTED FOR FDA PRIORITY REVIEW *PHASE 3 DATA SHOW DUPIXENT REDUCED NASAL SIGNS AND SYMPTOMS *MEDICINE ACCEPTED FOR PRIORITY REVIEW BY US FDA WITH A TARGET ACTION DATE OF FEBRUARY 28, 2026
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.